Mologen announces capital increase

Berlin, December 20, 2002

Mologen Holding AG yesterday has executed a capital increase against cash deposit with the exclusion of purchase rights of shareholders, creating new shares from the granted capital stock.

The number of shares increases from 4,980,331 about 131,000 to 5,111,331, corresponding to an increase of the subscribed capital of 3,80% to EUR 5,111,331. The issue price of the new shares was determined at EUR 2,36 per share and is close to the current market price calculated as a 30-day-average of the closing price at the Frankfurt stock exchange, with a discount of 9,58%.

The capital increase fosters the financial power of the company. Mologen estimates liquid means to amount to approx. 4.4 Mill. EUR at the end of the year.

The board of executives intends to use the additional cash to broaden the company´s technological portfolio in the area of tumor therapy.

Mologen went public in 1998 as one of the first biotechnology companies in Germany. The shares of Mologen are being traded in the Regulated Market on the Frankfurt Stock Exchange.

Mologen develops and utilizes new gene-based technologies for preventing and curing diseases. The main focus of development is on the MIDGE technology, which has been patented by Mologen. This is the ideal tool for deploying genetic information safely and efficiently as a medicine.

contact: Matthias Reichel, phone: +49-30-857 576 0, Fax: +49-30-857 576 50, e-mail: [email protected]